Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 10/20 | 0.59 |
| ▸ | MAPT | P10636 | 10/20 | 0.59 |
| ▸ | NPC1 | O15118 | 10/20 | 0.55 |
| ▸ | RAB9A | P51151 | 10/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | PKM | P14618 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.54 |
| ▸ | RELA | Q04206 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384688 | 0.84 | MAPT (0.70) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15916250 | 0.75 | RAB9A (0.67) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31622377 | 0.75 | TP53 (0.56) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17770342 | 0.73 | DHODH (0.76) | NPC1RAB9ASMN1; SMN2ALDH1A1PKM | |
| SCHEMBL3109465 | 0.73 | NPC1 (0.77) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15401671 | 0.73 | MAPT (0.64) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30472740 | 0.72 | KCNMA1 (0.64) | MEN1KMT2AKCNMA1ALOX15 | |
| SCHEMBL14807083 | 0.71 | RAB9A (0.75) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14631274 | 0.71 | MAPT (0.71) | TP53MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14654072 | 0.71 | RAB9A (0.71) | TP53MAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | claimed |
| US-9266872-B2 | 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2016-02-23 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | TMPRSS2, TMPRSS4, PRSS2 | TP53 1111/4885MAPT 4549/4885NPC1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.